Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

NEKTAR THERAPEUTICS

(NKTR)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
 SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Most relevant news about NEKTAR THERAPEUTICS
11/30Nektar Therapeutics Announces Data Presentations for Its Immuno-Oncology Programs At th..
CI
11/15Nektar Therapeutics Strengthens Board of Directors with Appointment of Diana M. Brainar..
PR
11/15Nektar Therapeutics Strengthens Board of Directors with Appointment of Diana M. Brainar..
CI
11/12Nektar Therapeutics Announces Data Presentations for Its Immuno-Oncology Pipeline at th..
PR
11/09Nektar Therapeutics to Host Webcast Conference Call for Analysts & Investors with Cance..
PR
11/08Benchmark Upgrades Nektar Therapeutics to Buy From Hold; Price Target is $20
MT
11/05Nektar Therapeutics Q3 Loss Widens as Revenue Drops; Shares Slump 21%
MT
11/05Oppenheimer Adjusts Nektar Therapeutics PT to $21 From $25, Maintains Perform Rating
MT
11/04Nektar Therapeutics Reports Third Quarter 2021 Financial Results - Form 8-K
PU
11/04Nektar Therapeutics Re-Affirms Financial Guidance for 2021
CI
11/04NEKTAR : Q3 Earnings Snapshot
AQ
11/04Nektar Therapeutics Reports Earnings Results for the Third Quarter and Nine Months Ende..
CI
11/04Earnings Flash (NKTR) NEKTAR THERAPEUTICS Reports Q3 Revenue $24.9M, vs. Street Est of ..
MT
10/26Nektar to Announce Financial Results for the Third Quarter 2021 on Thursday, November 4..
PR
09/22NEKTAR THERAPEUTICS : Thinking about trading options or stock in Ambarella, Robinhood Mark..
PR
More most relevant news
All news about NEKTAR THERAPEUTICS
11/30Nektar Therapeutics Announces Data Presentations for Its Immuno-Oncology Programs At th..
CI
11/15NEKTAR THERAPEUTICS : Change in Directors or Principal Officers (form 8-K)
AQ
11/15Nektar Therapeutics Strengthens Board of Directors with Appointment of Diana M. Brainar..
PR
11/15Nektar Therapeutics Strengthens Board of Directors with Appointment of Diana M. Brainar..
CI
11/12Nektar Therapeutics Announces Data Presentations for Its Immuno-Oncology Pipeline at th..
PR
11/09Nektar Therapeutics to Host Webcast Conference Call for Analysts & Investors with Cance..
PR
11/08Benchmark Upgrades Nektar Therapeutics to Buy From Hold; Price Target is $20
MT
11/05Nektar Therapeutics Q3 Loss Widens as Revenue Drops; Shares Slump 21%
MT
11/05Oppenheimer Adjusts Nektar Therapeutics PT to $21 From $25, Maintains Perform Rating
MT
11/05NEKTAR THERAPEUTICS Management's Discussion and Analysis of Financial Condition and Re..
AQ
More news
News in other languages on NEKTAR THERAPEUTICS
11/05La perte de Nektar Therapeutics au troisième trimestre se creuse alors que les revenus ..
11/04Nektar Therapeutics réaffirme ses prévisions financières pour 2021
11/04Earnings Flash (NKTR) NEKTAR THERAPEUTICS annonce un chiffre d'affaires de 24,9 million..
09/23Redhill Biopharma, AstraZeneca, Nektar Therapeutics règlent le litige relatif au brevet..
09/21Nektar Therapeutics s'associe à Pfizer et Merck pour un essai clinique
08/05Nektar Therapeutics fournit des prévisions de revenus pour l'année 2021
08/05Earnings Flash (NKTR) NEKTAR THERAPEUTICS annonce un chiffre d'affaires de 28,3 million..
07/22RedHill Biopharma et AstraZeneca règlent leur différend avec Apotex sur le brevet du gé..
06/14Exelixis collabore avec Bristol-Myers pour lancer une étude de phase précoce sur le méd..
05/20Les ventes d'initiés chez Nektar Therapeutics (NKTR) prolongent la tendance à la vente ..
More news
Analyst Recommendations on NEKTAR THERAPEUTICS
11/08Benchmark Upgrades Nektar Therapeutics to Buy From Hold; Price Target is $20
MT
11/05Oppenheimer Adjusts Nektar Therapeutics PT to $21 From $25, Maintains Perform Rating
MT
06/28NEKTAR THERAPEUTICS : Stifel Raises Nektar Therapeutics to Buy From Hold, Price Target to ..
MT
04/06NEKTAR THERAPEUTICS : SVB Leerink Adjusts Price Target on Nektar Therapeutics to $21 From ..
MT
02/22NEKTAR THERAPEUTICS : Benchmark Capital Downgrades Nektar Therapeutics to Hold From Buy
MT
More recommendations
Press releases
11/15NEKTAR THERAPEUTICS : Change in Directors or Principal Officers (form 8-K)
AQ
11/15Nektar Therapeutics Strengthens Board of Directors with Appointment of Diana M. Brainar..
PR
11/12Nektar Therapeutics Announces Data Presentations for Its Immuno-Oncology Pipeline at th..
PR
11/09Nektar Therapeutics to Host Webcast Conference Call for Analysts & Investors with Cance..
PR
11/05NEKTAR THERAPEUTICS Management's Discussion and Analysis of Financial Condition and Re..
AQ
More press releases
Upcoming event on NEKTAR THERAPEUTICS
Upcoming sector events